Long considered as no more than biological waste meant to be eliminated in urine, glucuronides have recently contributed to tremendous developments in the biomedical field, particularly against cancer. While glucuronide prodrugs monotherapy and antibody-directed enzyme prodrug therapy have been around for some time, new facets have emerged that combine the unique properties of glucuronides notably in the fields of antibody-drug conjugates and nanomedicine. In both cases, glucuronides are utilized as a vector to improve pharmacokinetics and confer localized activation of potent drugs at tumor sites while also decreasing systemic toxicity. Here we will discuss some of the most promising strategies using glucuronides to promote successful anti-tumor therapeutic treatments.

长期以来，葡糖苷酸被认为只不过是尿液中的生物废物，但最近为生物医学领域的巨大发展做出了贡献，特别是在抗癌方面。虽然葡糖苷酸前药单一疗法和抗体导向酶前药疗法已经存在了一段时间，但结合葡糖苷酸独特特性的新方面已经出现，尤其是在抗体-药物偶联物和纳米药物领域。在这两种情况下，葡糖苷酸都被用作载体以改善药代动力学并赋予强效药物在肿瘤部位的局部活化，同时还降低全身毒性。在这里，我们将讨论一些使用葡糖苷酸促进成功的抗肿瘤治疗的最有希望的策略。